Bio-Rad Reports First-Quarter 2024 Financial Results
May 7 (Reuters) - Diagnostics firm Bio Rad Laboratories (BIO.N), opens new tab reiterated its 2024 sales growth forecast on Tuesday, weighed by persistently weak spending by biotech companies and sluggish demand in China.
Bio-Rad’s Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare Conference
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the promotion of James J. Barry, currently Senior Vice President of Global Manufacturing, to the position of Executive Vice President and President of the Life Science Group, effective May 1, 2024. He succeeds Dr. Simon May, who has announced his decision to leave the company to pursue another professional opportunity.
Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
Bio-Rad’s Chief Operating Officer Andrew Last to Retire
Bio-Rad Reports Fourth-Quarter and Full-Year 2023 Financial Results
Bio-Rad to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024
Bio-Rad Reports Third-Quarter 2023 Financial Results
Oct 26 (Reuters) - Bio-Rad Laboratories (BIO.N) on Thursday lowered its annual revenue growth forecast, given the uncertain pace of the biopharma sector's recovery and ongoing macro challenges, sending the company's shares down about 11% in extended trading.